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The AXL receptor is a TAM (Tyro3, AXL, MerTK) re-
ceptor tyrosine kinase (RTK) important in physiolog-
ical inflammatory processes such as blood clotting,
viral infection, and innate immune-mediated cell
clearance. Overexpression of the receptor in a
number of solid tumors is increasingly appreciated
as a key drug resistance and tumor dissemination
mechanism. Although the ligand-receptor (Gas6-
AXL) complex structure is known, literature reports
on ligand-mediated signaling have provided conflict-
ing conclusions regarding the influence of other fac-
tors such as phosphatidylserine binding, and a
detailed, mechanistic picture of AXL activation has
not emerged. Integrating quantitative experiments
with mathematical modeling, we show here that
AXL operates to sense local spatial heterogeneity in
ligand concentration, a feature consistent with its
physiological role in inflammatory cell responses.
This effect arises as a result of an intricate reaction-
diffusion interaction. Our results demonstrate that
AXL functions distinctly from other RTK families, a
vital insight for the envisioned design of AXL-tar-
geted therapeutic intervention.
INTRODUCTION
TAM receptors are a receptor tyrosine kinase (RTK) family,
comprising Tyro3, AXL, and MerTK (TAM), which bind the li-
gands Gas6 and Protein S (Linger et al., 2008; Stitt et al.,
1995). These receptors have attracted considerable interest in
the past decade as a potential therapeutic target in a wide range
of cancers. While mutations driving oncogenesis have not been
identified and overexpression in the bulk tumor is typically not
striking, in solid tumors, overexpression of AXL in a subpopula-
tion of cells has strongly coincided with metastatic capacity,
invasiveness in vitro, and resistance to targeted therapies (Gjer-
drum et al., 2010; Holland et al., 2010; Hutterer et al., 2008;
Thomson et al., 2011; Zhang et al., 2008, 2012). Therapeutic
AXL inhibitors have shown promising results in combination
with other targeted or standard therapies and have potently
blocked metastasis (Gjerdrum et al., 2010; Holland et al., 2010;
Kariolis et al., 2014). Even after dissemination, targeting thedistinct population of AXL-expressing cells while simultaneously
targeting the bulk tumor with standard treatments may consider-
ably extendpatient survival (Bozic et al., 2013;Gupta et al., 2011).
MerTK and Tyro3 have separately been identified as therapeutic
targets in acutemyeloid leukemia, acute lymphoblastic leukemia,
glioblastoma, melanoma, non-small cell lung carcinoma, and
thyroid cancers, withmore consistent patterns of overexpression
(Graham et al., 1994, 2006; Lee-Sherick et al., 2013).
Therapeutically targeting the TAM receptors holds consider-
able promise and was initially motivated, in part, by the viability
of knockout animals (Lu and Lemke, 2001; Lu et al., 1999). How-
ever, further study has uncovered an important function of the re-
ceptors in diverse processes, cautioning against overly broad
therapeutic manipulation. As the retinal pigment epithelium and
Sertoli cells within the testes utilize TAM receptors for clearance
of cellular debris, inhibition leads to sterility and blindness (Bur-
styn-Cohen et al., 2012; Chen et al., 2009b; Lu et al., 1999; Pra-
sad et al., 2006). Themost studied effects of TAM knockout have
been in the immune system, where signaling from the receptors
couples clearance of cell debris to negative regulation of the
innate immune system (Carrera Silva et al., 2013; Lemke and
Rothlin, 2008; Rothlin et al., 2007). One of the striking pheno-
types of TAM triple-knockout mice is widespread accumulation
of apoptotic cell debris (Scott et al., 2001). Thus, it is perhaps
not surprising that an effect of TAM knockout is development
of autoimmune disorders, though it is unclear whether this is
due to accumulation of cross-presented auto-antigen, reduced
negative regulation, or both (Lu and Lemke, 2001). Some viruses,
in fact, take advantage of TAM signaling, using host-derived
phosphatidylserine (PtdSer)-exposed membranes (which bind
TAM ligand) to delay the immune response (Bhattacharyya
et al., 2013). Because of these roles for the TAM family, ap-
proaches to manipulate endogenous TAM signaling in immune
cells, if unwanted therapeutic side effects can be avoided, is a
promising avenue through which to modulate the cancer im-
mune response (Paolino et al., 2014). Indeed, blocking just
host TAMs can potently inhibit metastasis in murine breast, mel-
anoma, and colon cancer models (Cook et al., 2013).
While a great deal is known from genetic and structural
studies, study of these receptors is severely limited currently
by poor understanding of the relevant activation mechanisms
(Figure 1A) (Sasaki et al., 2006). The TAM ligands Gas6 and Pro-
tein S both bind PtdSer, and many studies have highlighted the
importance of this interaction to activation of TAM receptors,
though the exact means by which information is transduced
from lipid to receptor via ligand is controversial (Dormady
et al., 2000; Hall et al., 2002; Hasanbasic et al., 2005; RajotteCell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc. 25
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Figure 1. AXL Phosphorylation Response Is Complex and Distinct across Timescales, and It Requires Gas6-PtdSer Interaction for Robust
Response
(A) Diagram of AXL-Gas6 interaction. Receptor and ligand interact through a high-affinity (brown, Ig1) and low-affinity (blue, Ig2) binding interface. These in-
teractions, only mediated through the SBHD domain, lead to receptor dimerization with no receptor-receptor ectodomain interactions. However, through
previously unknownmechanisms, PtdSer interaction via the Gla domain is known to be important to receptor activation. The structural aspects of TAM receptor-
ligand interaction are thought to be shared among all three TAM receptors and two ligands, although AXL lacks measurable binding to Protein S.
(B and C) ELISA-based quantitative measurement of AXL phosphotyrosine and total abundance upon treatment with indicated concentrations of Gas6
at 0–10 min (B) or 4 hr (C).
(D) Measurement of phosphotyrosine and total AXL in warfarin-treated A549 cells upon stimulation with DGla Gas6 for 1 or 4 hr. Red line shows corresponding
response measured upon stimulation with full-length Gas6 in (C). *p < 0.05 (significant change from untreated control), Student’s t test. RU, relative units.
(E) Measurement of phosphotyrosine AXL in warfarin-treated A549 cells upon stimulation with 1.25 nM DGla Gas6 over 10 min. Red line shows corresponding
response measured upon stimulation with full-length Gas6 in (D).
Error bars indicate SE of triplicate measurement.et al., 2008; Stenhoff et al., 2004; Yanagita et al., 1999). Earlier
work identified PtdSer as an important factor to TAM activation,
although it concluded that interaction between the ligand and re-
ceptor was entirely dependent upon lipid interaction, which has
proven to not be the case (Nakano et al., 1997; Tanabe et al.,
1997). More recent work has revisited the influence of PtdSer
binding, showing that its effect is not due to a change in recep-
tor-ligand association and depends strongly on the spectrum
of TAM receptors expressed, but has come to somewhat con-
flicting conclusions regarding which contexts require PtdSer
for robust activation (Lew et al., 2014; Tsou et al., 2014). Studies
to date have relied on stimulation with PtdSer and TAM ligand
either with or without the ability to bind PtdSer, and, in doing
so, have ignored the influence of autocrine ligand and PtdSer
sources. The absence of a quantitative and mechanistic under-
standing of TAM receptor activation is the likely source of
seemingly conflicting conclusions and prevents not only rational
targeting of the receptors but also understanding their role in
diverse physiological processes.
To improve our understanding of AXL signaling, we con-
structed and validated a reaction model of receptor-ligand
engagement, trafficking, and activation. Using combined simula-26 Cell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc.tion and experimental validation, we demonstrate that AXL
robustly senses local regions of ligand stimulation, strongly
dominating over uniform ligand presentation. We show that
autocrine ligand strongly influences receptor response and that
kinetic measurement is absolutely necessary to capture the rela-
tive signaling capacity of treatment conditions. Specific sensing
of ligand spatial distribution is a critical feature for function
of TAM receptors, particularly in sensing cellular debris. This
elegant higher order interaction between reaction and diffusional
processes within an RTK emphasizes the importance of our
combined experimental and modeling approach to understand-
ing the intricately patterned extracellular environment.
RESULTS
Complexity of the AXL Response to Ligand
To investigate the basis for the complex and, at times, confound-
ing published data on ligand-induced AXL signaling, we exam-
ined a panel of AXL-expressing cancer cell lines by quantitative
measurement of their dynamic response to Gas6 treatment
using anti-AXL antibodies bound to beads. AXL constituted
>95% of TAM receptor in the AXL-positive cell lines used
(Figure S1A). To ensure the specificity of our bead-based activa-
tion quantitation, we measured receptor phosphorylation upon
transfection with either full or kinase-dead AXL in MDA-MB-
453 cells lacking endogenous AXL expression, as well as
knocked-down AXL expression inMDA-MB-231 cells that do ex-
press AXL (Figures S1A and S1B).
Next, we treated a panel of cancer cell lines overexpressing
AXL with varying doses of Gas6 and measured their dynamic
response to stimulation (Figure S1); A549 cell line behavior is
featured as a leading example (Figures 1B–1E). Depending
upon the cell line, Gas6-elicited AXL phosphorylation displayed
either a transient peak (<5 min) that rapidly returned to near-
baseline levels or a monotonic increase in phosphorylation at
high doses with relatively little response to lower doses of ligand
(Figures 1B and S1C). At longer times, Gas6 stimulation could
induce up to an 8-fold increase in the fraction of activated recep-
tor (Figure S1D), 3-fold in A549 cells (Figure 1C). Notably, the
magnitude of transient responses did not correspond to those
at longer times (Figures 1B, 1C, S1C, and S1D). These dynamics
of response are strikingly distinct from those of ErbB and other
known RTK signaling paradigms in which receptor activation oc-
curs very rapidly and robustly, with a straightforward relationship
with respect to receptor and ligand concentrations at short and
long timescales (Chen et al., 2009a; Kim et al., 2011; Kleiman
et al., 2011). Application of the AXL-activating antibody AF154
produced a rapid and strong phosphorylation response, con-
firming that the complex responses to Gas6 are a feature of
AXL ligand-dependent ectodomain regulation (Figure S1E).
In total, we observed that AXL displayed unusual activation ki-
netics, suggesting a more complex relationship between recep-
tor abundance and ligand concentration than observed for other,
well-characterized ligand-receptor systems. Specifically, the
AXL response to Gas6 lacks a uni-modal relationship to ligand
concentration and displays differing responses on distinct time-
scales. These data highlight the importance of quantitative, dy-
namic measurements, as these complex responses indicate
any dose-response relationship is highly dependent upon the
duration of the assay and cellular system.
Gas6-PtdSer Interaction Is Essential to Robust
Long-Term AXL Phosphorylation
Gas6 interaction with PtdSer via its Gla domain (Figure 1A) has
been reported as essential for robust activation of AXL (Lew
et al., 2014). We hypothesized that contribution of the Gas6-
PtdSer interaction may confound simple interpretation of the
activation kinetics we observed.
To examine the contribution of the Gas6-PtdSer interaction to
autocrine activation of AXL, we treated four cancer cell lines with
warfarin, which blocks g-carboxylation of the Gas6 Gla domain
and, therefore, Gas6-PtdSer interaction. In each case, treatment
with warfarin largely inhibited Gas6 g-carboxylation, corre-
sponding to no change or a decrease in AXL phosphorylation
(Figures S2A andS2B). Concomitant changes in trafficking occur
with inhibition of any RTK, and we found it necessary to measure
total AXL abundance as well to fully capture the effect of warfarin
(Figure S2A). Notably, we still measured AXL phosphorylation in
the presence of warfarin and a different effect upon small-inter-
fering-RNA (siRNA)-mediated knockdown of Gas6, indicating
that PtdSer interaction is not strictly essential for activation (Fig-ure S2A). The increase in total AXL abundance with BT-549
might occur, owing to a reduction in phosphorylation-dependent
trafficking, while the decrease in AXL abundance with U87 may
suggest that Gas6-PtdSer interaction partially reduces the rate
of receptor clearance (Figure S2A).
Next, we utilized Gas6 lacking the Gla domain (DGla Gas6),
combined with warfarin pretreatment, to entirely eliminate the
contribution of Gas6-PtdSer interaction (Kariolis et al., 2014).
Then, we measured phosphorylated, total, and surface AXL
abundance in A549 cells over a range of DGla Gas6 concentra-
tions at 1 and 4 hr after stimulation (Figure 1D). While phosphor-
ylated and surface receptor abundance were not significantly
changed by increasing amounts of DGla Gas6, we did observe
an increase in total receptor abundance (Figure 1D; Student’s
t test, p < 0.05). To examine the potential for a distinct transient
response, we stimulated A549 cells with 1.25 nM DGla Gas6
after warfarin pretreatment. Surprisingly, we observed a similar
response to full-length Gas6 on short (<5 min) timescales (Fig-
ure 1E). Thus, high concentrations of Gas6 in the absence of
PtdSer interaction can be, in fact, inhibitory of receptor activation
on longer timescales, and generalization of this contribution of
PtdSer to either simply ‘‘activating’’ or ‘‘inhibitory’’ is an oversim-
plification of a complex dynamic response (Lew et al., 2014;
Tsou et al., 2014).
A Reaction Model of AXL Signaling Integrates Structural
and Kinetic Understanding
To interpret our measurements in a mechanistic manner, we
used a PtdSer-independent reaction model of AXL signaling.
We assembled a kinetic differential equation model of recep-
tor-ligand binding, dimerization, and activation, incorporating
current structural understanding of TAM-ligand binding (Fig-
ure 2A). TAM receptor ligand bridges two receptors with asym-
metric affinity for each in a mirrored arrangement (Sasaki et al.,
2006). Receptor trafficking was extrapolated from knowledge
of other RTK families (French and Lauffenburger, 1997; Monast
et al., 2012). Briefly, new receptor synthesis occurs at a constant
rate; endocytosis occurs at both an activation-dependent rate
and an activation-independent rate; and recycling/degradation
occur at set rates, with a sorting fraction determining fate for
each species dependent upon activation state (Figure 2B). A0,
A1, A2, and A12 represent monomeric AXL with Gas6 bound
nowhere, at the high-affinity site, at the low-affinity site, or at
both sites, respectively (Figure 1A). D1 and D2 represent dimers
formed by bridging receptors via one or two ligands, respec-
tively. We measured minimal shedding of AXL (0.16% ± 0.03%
that of cell-associated receptor after 24 hr in A549) and so disre-
garded it as a mechanism of negative regulation.
With a model for AXL activation, we then sought to identify the
rates of various binding reactions that could produce our obser-
vations for DGla Gas6, again featuring the A549 cell line as a
central example (Figures 2C–2E). We simulated our model
across thousands of independent runs and calculated its fit to
the DGla Gas6 A549 data, optimizing the fit of the remaining 11
parameters using direct search (Audet et al., 2008). Our model
was able to broadly capture our measurements of A549 cell
stimulation with DGla Gas6 in the absence of PtdSer interaction
(Figure 2C), as well as in U87 cells as a second line (Figure S3).
As multiple combinations of parameters were able to fit ourCell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc. 27
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Figure 2. A Reaction Model of AXL Signaling Integrates Structural and Kinetic Understanding
(A) Diagram of the AXL reaction model. Trafficking is not shown. Binding reactions occur identically with internalized and surface species.
(B) Model of AXL trafficking. Receptor expression occurs constitutively. Endocytosis occurs at a basal and activation-dependent rate. Recycling and degradation
occur at prescribed rates, with a sorting fraction to determine which occurs. fx is 1 for phosphorylated species and felse for all other species. Some parameters
were fit within their indicated range (red), while others were constrained by detailed balance (green) or assumptions (black).
(C) Measurements compared with simulations from all parameter fits within 5% likelihood of the optimal fit. RU, relative units.
(D) Parameter values observed in all fits with a relative likelihood within 5% that of the optimal fit.
(E) Sum-of-squared error for the best-fit parameter sets in which species D1 is either active or inactive.measurements, we considered all good fits simultaneously to
ensure robustness of our model interpretation. Examining each
set of parameters within 5% likelihood of the optimally fit param-
eter set revealed that many parameters were, in fact, partially
identifiable, so that many parameters only fit within a limited
range (Figure 2D). For example, the influence of autocrine
Gas6 was absolutely essential to fitting the observed responses,
and the affinity of the receptor dimerization (kf1) reactions was
constrained within a subset of the allowed parameter range.
The importance of autocrine Gas6 is perhaps trivially evident,
since some amount of phosphorylation exists in A549 cells
before exogenous stimulation (Figure 1D). Experimental evi-
dence does not yet exist for whether the D1 species is an active
form of AXL; however, fitting significantly selected it as a phos-
phorylated species (Figure 2E). This is consistent with our obser-28 Cell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc.vation that the AXL-activating antibody AF154, which dimerizes
the receptor but surely does not do so in the exact conformation
of species D2, can robustly produce receptor phosphorylation
(Figure S1E).
Reaction Model Identifies Local Receptor
Concentration as Limiting to Robust Response
With amodel capturing the effects ofDGla Gas6, we then sought
to understand parameters that might influence receptor activa-
tion, particularly as RTK activation upon stimulation is typically
100-fold or greater in magnitude. We individually varied each
fit non-trafficking parameter within 1,000-fold of its value for
each set of optimal fits (Figure 3A). Each parameter set
agreed that increasing the forward rate of receptor dimerization
(kf1) should increase the amount of phosphorylated receptor
A B
C
D E
F G
Figure 3. A PtdSer-Independent and a Reaction-Diffusion Model Indicate that Local Receptor Concentration Is Rate Limiting for Robust
Activation
(A) The relative fraction of activated receptor upon variation of each reaction parameter. Response is shown for stimulation with 10 nM Gas6 for 4 hr.
(B) Fractional vacancy of Ig1- (red) and Ig2 (black)-binding sites based on fit or measured affinities at equilibrium. The bars above indicate the range of ligand
concentrations tested in experiments. Each black line indicates a distinct parameter set.
(C) Schematic of the finite differencing model. Diffusion was allowed within a radially symmetric region of interest. Peak Gas6 amount was held constant while
varying spatial profiles of concentration. Spatial inhomo. param., spatial inhomogeneity parameter; AU, arbitrary units.
(D) Average and peak concentration for differing Gas6 spatial profiles.
(E) Modeling output for AXL phosphotyrosine density at the peak point of Gas6 (r = 0) at 30min with respect to varied Gas6 concentration profiles. Autocrine Gas6
levels and AXL expression were set to A549 levels. D indicates distinct diffusion coefficients specified in length units of the region of interest.
(F) Modeling output for overall AXL phosphotyrosine under identical conditions.
(G) Modeling output of surface species abundance at 30 min under identical conditions.observed (Figure 3A). This suggests that receptor dimerization is
a limiting step to activation of AXL, regardless of the Gas6 con-
centration, and that factors increasing the local receptor con-
centration (thus increasing the forward dimerization rate) would
lead to a Gas6-mediated response.
With a fit for the parameters characterizing ligand binding, we
additionally sought to understand the ligand occupancy of each
binding site over a range of ligand concentrations at equilibrium.
The measured affinity of Gas6-AXL binding via the immunoglob-
ulin (Ig)1 domain is exceptionally high, and nearly all sites are
bound at all doses of Gas6 used (Figure 3B). Model fits of Ig2
domain affinity were consistent with previous measurements of
Gas6-AXL affinity measurements in the presence of Ig1-interac-
tion mutants (Sasaki et al., 2006), and they suggest that the
domain is almost entirely unbound based on the bulk concentra-
tion of ligand alone (Figure 3B). The range of Gas6 concentra-tions in which we observed some accumulation of total AXL
overlapped with the range at which some fraction of Ig2 began
to be bound, suggesting that bulk Ig2 occupancy may explain
this inhibition observed, since, by far, the predominant form of
AXL on the cell surface would be A1 (bound only at Ig1), and
AXL bound at both Ig1 and Ig2 (A12) would be inhibited from
dimerization with this species. Thus, very high uniform concen-
trations of Gas6 may be, in fact, inhibitory, due to soluble ligand
binding the Ig2 domain, thus preventing dimerization.
We further hypothesized that Gas6-PtdSer interaction may
drive AXL activation through relocalization of ligand to localized
regions of the cell surface, corresponding to an effective in-
crease in the rate of receptor dimerization. To more directly
test this, we extended our model to account for spatial heteroge-
neity and diffusion of receptor, by means of finite differencing
(Figure 3C). We created a radially symmetric region of interestCell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc. 29
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Figure 4. Spatially Localized Ligand Presentation Underlies Robust Autocrine AXL Activation
(A) Immunofluorescence of AXL localization with or without warfarin treatment.
(B) Quantification of mean AXL immunofluorescence intensity (left) and the fraction of pixels 5-fold above mean AXL intensity under each condition. Error bars
indicate Tukey plots. ***p < 0.001 (Wilcoxon rank-sum test).
(C) Cumulative distribution of AXL staining pixel intensities for BT549 cells with (green) or without (black) warfarin treatment. Both the intensity and remaining
cumulative distribution density axes are presented on a log scale for ease of visualization.
(D) Coimmunoprecipitation of AXL and Gas6 in MDA-MB-231 cells in the presence or absence of warfarin. Asterisk in lower blot marks the expected size of Gas6.(meant to represent a small portion of the cell surface), in which
the concentration of Gas6 may be varied to be more uniform or
alternatively concentrated in the center (Figure 3D). Diffusion is
the only process defining spatial scale, so it was defined in units
of the region’s radius. In contrast to the homogeneous model,
local stimulation was predicted to cause much stronger and
sustained local receptor phosphorylation (Figure 3E) and, in
fact, greater total receptor phosphorylation (Figure 3F). By
investigating the components of the model, we determined
that this increased activity corresponded to an increase in
abundance of D1 and D2 (dimers with one or two ligands bound)
and A0 (entirely unbound receptor) (Figure 3F). Concurrently, this
shift led to a decrease in A1, A2, and A12 (receptor with ligand
bound at Ig1, Ig2, or both sites, respectively). Thus, our model
predicts that localized presentation of ligand may drive AXL acti-
vation, even in the absence of changes upon spatially uniform
stimulation.
Autocrine PtdSer Interaction Drives Punctate AXL
Localization
The phenotypes observed in TAM knockout mice suggest that
physiological signaling by these receptors principally arises
from engagement of ligand immobilized on PtdSer-presenting
surfaces, such as apoptotic cell debris, viral envelopes, and
photoreceptor outer segments (Bhattacharyya et al., 2013;
Lemke and Rothlin, 2008). Presentation of ligand immobilized
on such surfaces would likely limit presentation of ligand to a
restricted portion of the cell surface. We hypothesized that this
might be a mechanism of increasing local receptor concentra-30 Cell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc.tion using the exceptionally high affinity of Ig1. Higher local re-
ceptor concentration would exactly correspond to higher effec-
tive dimerization rates in our model, as these parameters are the
only rates influenced by receptor density. Thus, our model pre-
dicts that local receptor density would directly lead to activation.
Indeed, immunofluorescence of two cell lines with autocrine
activation of AXL revealed punctate staining of the receptor on
thecell surfaceand that this localizationwasablateduponwarfarin
treatment (Figure 4A). While similar total staining for AXL was
observed in both cell lines with warfarin treatment, there was a
complete removal of dense receptor clusters (Figure 4B). Exami-
nation of the distribution of receptor densities showed a shift in re-
ceptor distribution to regions of lower receptor density (Figure4C).
Notably, a change in receptor-ligand interactionwasnot observed
with warfarin treatment, indicating that warfarin-associated activ-
ity changesarenot a consequenceof changes in the amount of re-
ceptor-associated Gas6 (Figure 4D). AXL-Gas6 interaction re-
quires calcium, and so 5 mM EDTA lysate treatment was used
as a negative control (Sasaki et al., 2006; Ekman et al., 2010).
ABiphasicRelationship to LipidConcentration Validates
the Importance of Ig1-Driven Receptor Localization
Last, we tested, through a variety of experiments, whether
PtdSer-dependent AXL activity requires Ig1-mediated localiza-
tion of AXL. First, we utilized 0.25 nM Gas6 to ensure that nearly
all Ig1, but few Ig2, binding sites were occupied (Figure 3B) (Sa-
saki et al., 2006). Stimulating with just Gas6 resulted in essen-
tially no change in receptor phosphorylation, as observed before
(Figures 1B and 5A; Figure S1C). However, exogenous addition
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Figure 5. Validation of the Spatial AXL Signaling Model
(A) Measurements of AXL pan-pY in MDA-MB-231 (top) and A549 (bottom) upon stimulation with PtdSer-containing vesicles in the presence of 0.25 nM Gas6.
13 and 1/103 lipid concentrations correspond to 100 mg/ml and 10 mg/ml of lipid, respectively.
(B) Measurement of cell-associated Gas6 with A549 cells stimulated with Gas6 in the presence or absence of lipid. Inset shows amount of Gas6 quantified with or
without cells present for the 1.25 nM Gas6 condition. RU, relative units.
(C) Measurement of AXL phosphorylation at 10 min in BT-549 cells in response to 1.25 nMGas6 with or without warfarin pretreatment and with or without the Gla
domain present in the exogenous ligand.
(D) Diagrammatic explanation of the basis for a biphasic response with respect to lipid concentration. At low concentrations of PtdSer-containing lipid, receptor
partitions into local regions, resulting in robust activation. At very high lipid concentrations, PtdSer interaction is ubiquitous. Thus, even though receptor partitions
into PtdSer-interacting regions, this does not result in high local receptor density.
(E) Prediction and measurement of AXL phosphorylation at 30 min with varying amounts of PtdSer-containing vesicles and 0.25 nM Gas6.
(F) Phosphotyrosine immunofluorescence (top) ofMDA-MB-231 cells starved and stimulatedwith polystyrene beads coatedwith BSA or Gas6, and quantification
of the immunofluorescence (bottom, n > 10). Cells were stimulated for 30 min prior to fixation.
Error bars indicate the SE of triplicate measurements, unless indicated otherwise.of PtdSer-containing vesicles could increase AXL phosphoryla-
tion, and this was synergistically increased by the addition of
this low concentration of Gas6 (Figure 5A). Notably, addition of
PtdSer did not affect the amount of cell-associated Gas6 (Fig-
ure 5B). Next, we wanted to test whether receptor clustering,
and not Gas6-PtdSer interaction itself, was driving Gas6-
PtdSer-interaction-mediated signaling. We did this in BT-549
cells, which, owing to their 5-fold lower AXL expression (Fig-
ure S1A) and high degree of autocrine-mediated clustering (Fig-
ure 4B), should be highly dependent upon localized receptor for
signaling. Indeed, DGla Gas6 provided a response upon stimula-
tion but only if autocrine Gas6-PtdSer interaction was present to
localize the receptor (Figure 5C).
The contribution of PtdSer in terms of localizing AXL and inter-
acting with Gas6 may be discriminated at sufficiently high con-
centrations of lipid, in which sufficient lipid is present so as to
completely cover the cell surface (Figure 5D). At low concentra-
tions of lipid, receptor preferentially partitions into regions of
Gas6-PtdSer interaction, leading to a high local receptor density
and driving receptor dimerization and activation. At high concen-
trations of lipid, even though receptor still partitions into regions
of Gas6-PtdSer interaction preferentially, this does not result in a
high local receptor density. More specifically, observing that
the relationship between local receptor density and activity is
roughly proportional (Figure 3A), and that clusters contain
roughly 5-fold more AXL than the surrounding cell surface
(Figures 4A–4C), we can specifically predict the relationshipbetween AXL phosphorylation and lipid concentration for a con-
stant concentration of Gas6. Again, we utilized a low concentra-
tion of Gas6, varying the concentration of stimulated lipid, and,
indeed, observed a biphasic (increasing, then decreasing) rela-
tionship between lipid concentration and AXL phosphorylation
(Figure 5E). This points to changes in AXL localization giving
rise to the effect of Gas6-PtdSer interaction predominantly rather
than a conformational change due to PtdSer interaction itself.
Indeed, upon coupling Gas6 to polystyrene beads, we could
observe spots of intense phosphotyrosine staining dependent
upon surface presentation of the ligand, suggesting that lipid is
dispensable in the presence of another receptor localization
mechanism (Figure 5F).
DISCUSSION
The importance of PtdSer interaction to robust activation of TAM
receptors has been appreciated for almost 2 decades, yet a
molecular understanding of this effect has not developed
(Nakano et al., 1997; Tanabe et al., 1997). Here, our combined
experiment/modeling study provides a quantitative, mechanistic
understanding of TAM signaling and, in doing so, provides
essential information for the specific targeting of TAM signaling
during both dysregulation and normal function (Figure 6). As all
three TAM receptors are expected to bind both Gas6 and Protein
S in a similar fashion, the methods used here should be appli-
cable to understanding signaling in many diverse contexts inCell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc. 31
Figure 6. Model for Efficient Activation of
AXL Signaling
In the low Gas6 regime, the low-affinity site is
insufficient for receptor dimerization and activation
by ligand. In the presence of a high, uniform con-
centration of Gas6, occupation of the low-affinity
site acts as a competitive inhibitor, since the A12
species is unable to dimerize with itself. Only with
presentation of localized Gas6 is strong receptor
activation observed, driven by diffusional influx of
receptors from regions of low Gas6 concentration.
This provides the appropriate localized signal for
function of the receptor as a marker for PtdSer
exposure.which TAM signaling plays a role. The fact that blocking PtdSer
interaction has distinct effects dependent upon the cell line used
clearly emphasizes the need for mechanistic, molecular under-
standing of TAM receptor activation and that PtdSer does not
have a simply activating or inactivating role (Figures 1B, 1E,
and 5E). Future studies, utilizing engineered vesicular constructs
with specific properties, will be necessary to exactly define con-
ditions of optimal TAM receptor activation.
In essence, synergy upon local stimulation is driven by asym-
metry between binding sites in the affinity of ligand for receptor
(Figure 3B). While most high-affinity sites (Ig1) are constitutively
occupied with ligand, the low-affinity site (Ig2) is of insufficient
affinity to drive dimerization of receptor. Localized presentation
of ligand, however, paired with diffusional sampling of receptor
within the cell surface, allows the high-affinity site Ig1 to drive re-
localization of receptor so that patches of ligand also have very
high concentrations of receptor. These local regions of increased
ligand and receptor concentration promote binding at the low-
affinity site Ig2 for ligands already bound at the high-affinity
site Ig1. Notably, simply raising the concentration of ligand
further does not have the same effect and, in fact, acts as a
competitive inhibitor of receptor activation for certain ligand con-
centrations, since receptor activation requires pairing of comple-
mentarily bound/unbound receptors (Figure 2C).
Not only do local patches of stimulation have a locally higher
concentration of ligand, but also diffusional sampling of the re-
ceptor, followed by binding, results in a higher local concentra-
tion of receptor, shifting the behavior of the system. The passive,
specific contrast sensor this creates is vital to the normal phys-
iological role of AXL as a trigger for phagocytic uptake of cellular
debris. Whereas other RTK ligands can provide localized
chemotactic cues, this particular system more exclusively per-
mits AXL-expressing cells to express Gas6 and only trigger
AXL activation when the ligand is trapped by PtdSer-presenting
surfaces (Figure 5A). In contrast to chemoattractive cues, which
arise through paracrine communication, the targets of TAM
signaling need not synthesize growth factor. Through this sys-
tem, a phagocytic cell can synthesize all the components32 Cell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc.needed for RTK activation, including
growth factor, and then PtdSer exposure
on the target debris can provide the
specific relocalization cue for activation.
Synthetic circuits have been previously
designed for detection of input disconti-nuities, to the exclusion of overall input magnitude, but have so
far relied upon opposing influence of a locally activating input
and diffusing negative regulator (Tabor et al., 2009). TAM
signaling, in contrast, relies upon the higher order effects arising
from diffusion of the receptor itself to create such a system in the
absence of a separate, diffusible, negative regulator.
In the context of cancer therapy, our results suggest that
multiple mechanisms exist for modulating AXL activity within
the tumor environment. Tumor cells may take advantage of
spatial ligand heterogeneity to upregulate AXL signaling, and
the signaling may be directly upregulated by this mechanism
through PtdSer exposure upon chemotherapeutic-induced
apoptosis (Dunne et al., 2014). AXL expression in tumor cells
may not only sequester PtdSer-presenting debris on the tumor
cell surface but also cause juxtacrine signaling upon interaction
with TAM-expressing immune cells to block immunosurveil-
lance (Paolino et al., 2014). While true cancer-cell-specific tar-
geting of AXL signaling is likely impossible, carefully engineered
Gas6-binding mutants may show some specificity for dysregu-
lated signaling, which is important given recent reports of
negative consequences for broad TAM inhibition (Bosurgi
et al., 2013). Specifically, our modeling identifies that Ig2-Gas6
binding is relatively weak yet required for both PtdSer-depen-
dent and PtdSer-independent signaling and, therefore, may
represent a potent site of competitive inhibition (Figure 3B).
More practically, study of AXL signaling has been limited by
seemingly limited responses to ligand stimulation, sometimes
attributed to ligand quality. Our model and quantitative analysis
identify conditions of robust AXL response and integrate under-
standing of receptor function to show that soluble ligand stimu-
lation as typically performed is not the representative activation
mechanism and that localized receptor activity is likely to be
most important to AXL function. Modulating TAM signaling
with improved knowledge of MerTK and Tyro3 as well, both
as a marker for apoptotic clearance and as a negative regulator
of the immune response, holds immense promise in modulating
the cancer immune response (Lemke and Rothlin, 2008; Paolino
et al., 2014).
More generally, kinetic modeling provides a framework for the
elucidation of many complex aspects of RTK signaling and inte-
gration of extant knowledge. While ligand presentation is intri-
cately controlled within the in vivo environment, such as by
growth factor binding to fibrillar matrix, reaction-diffusion inter-
actions have not been extensively identified (Casaletto and
McClatchey, 2012). Beyond PtdSer, other factors in the extracel-
lular environment may be able to relocalize TAM receptors in a
similar manner by binding to ligand or receptor and, thus,
potently activate the receptors. Other receptors, even if mostly
responsive to ligand concentration, are still likely to be modu-
lated in important ways by localized presentation of ligand.
These complex effects will only be understood through detailed
mechanistic modeling due to the experimental difficulty inmodu-
lating and measuring these effects. Ligand concentration is only
one property of the extracellular environment useful formeasure-
ment, andwe anticipate that future investigations will reveal simi-
larly elegant sensing solutions designed by natural selection.
EXPERIMENTAL PROCEDURES
Reagent Preparation and Cell Culture
MDA-MB-453, SKBR3, MDA-MB-231, A549, BT-549, A172, MCF7, and U87
cells were obtained from ATCC. All cells were grown in DMEM supplemented
with 10% FBS and antibiotics, except for BT-549 cells, which were grown in
RPMI-1640 with 10% fetal bovine serum (FBS) and antibiotics. g-carboxylated
Gas6 purified from an NS0 culture in the presence of vitamin K was obtained
fromR&DSystems. AGas6mutant containing only the Laminin G-like domains
and part of the last epidermal growth factor (EGF) domain was graciously pro-
vided by the J. Cochran lab (Kariolis et al., 2014; Sasaki et al., 2006). Warfarin
(Sigma-Aldrich) was added where indicated, 24 hr prior to analysis at
100 mg/ml, along with new media. All ELISA measurements were performed
in multiplexed fashion, using individually identifiable beads (Luminex). Briefly,
beads were sedimented for 3 min at 1043 g and then resuspended in 80 ml of
100 mM NaH2PO4 (pH 6.3). 10 ml of 50 mg/ml S-NHS and 10 ml of 50 mg/ml
EDC were added, and the mixture was incubated with agitation for 20 min at
room temperature. Beads were then pelleted and resuspended in 300 ml of
50 mM HEPES (pH 7.4), with 0.1 mg/ml of either AXL, MERTK, TYRO3, or
Gas6 capture antibody (R&D Systems). The mixture was incubated overnight
at 4C with agitation. The next day, the beads were washed repeatedly and
stored in 1% BSA in PBS. Coupling efficiency was measured using bio-
tinylated protein G. Cells were always lysed in 50 mM Tris, 10% glycerol,
150 mM NaCl, 1% NP-40 (pH 7.5), with cOmplete protease inhibitor (Roche)
and Phosphatase Inhibitor I (Boston Bioproducts).
Quantification of Receptor Abundance, Shedding, Phosphorylation,
and Cell-Associated Ligand
For lipid stimulation, 5:3:2 w/w phosphatidylethanolamine:PtdSer:phosphati-
dylcholine (Avanti Polar Lipids) was resuspended in L15 media with 0.35%
BSA at 4mg/ml, vortexed vigorously, and then diluted to the indicated concen-
tration. 0.25 nM Gas6 was added where indicated, and the mixture was incu-
bated with gentle shaking for 1 hr. Cells were starved for 4 hr and then were
treated and lysed.
Protein concentration was measured by bicinchoninic acid assay. Lysates
were incubated with capture beads overnight with agitation, then washed
with 0.1% Tween 20 in PBS, and incubated with either detection antibodies
for each TAM receptor (R&D Systems) or biotinylated 4G10 for 30 min.
After washing again, beads were incubated with streptavidin-phycoerythrin
for 10 min and then quantified using a FlexMap 3D (Luminex). Receptor
abundance was quantified by comparison to a recombinant standard (R&D
Systems).
Surface abundance was measured by surface biotinylation. After treatment
for the indicated time, cells were washed repeatedly with ice-cold PBS and
then incubated at 4Cwith cell-impermeable sulfo-NHS-biotin for 30 min. Sur-
face labeling was halted by lysis. Capture beads were then incubated with thelysate overnight, and on the next day, labeling was quantified using streptavi-
din-phycoerythrin.
Cell-associated ligand was measured by repeatedly washing cells with PBS
and then measuring the amount of Gas6 present in the lysate. Receptor shed-
ding was quantified by incubating cells in serum-free medium in the presence
of either 0 or 1.25 nM Gas6 for 24 hr and then collecting the supernatant and
cell lysate. Supernatants were clarified by centrifugation at 3,000 3 g for
10 min to remove potential cell debris. Receptor abundance was then
measured in each fraction and adjusted by total volume to derive a total
amount in the supernatant or cell lysate.
Barium Citrate Precipitation and AXL Co-immunoprecipitation of
g-Carboxylated Gas6
After cells were lysed and lysate was clarified, 18 ml of 1 M BaCl2 was added
per 400 ml of lysate to each sample. Samples were incubated with end-over-
end mixing for 1 hr and then spun at 1043 g for 5 min at 4C to yield a precip-
itated pellet. The supernatant was removed and stored separately, and then
the pellet was resuspended in 0.1 BaCl2 and 0.1 M NaCl in ddH2O to wash.
Each sample was again incubated with mixing at 4C and then pelleted by
centrifugation. The pellet was resolubilized in a minimal amount of 0.5 M
EDTA (pH 8).
For AXL-Gas6 co-immunoprecipitation, lysates were incubated with 10 mg
AXL ELISA capture antibody or an IgG control (R&D Systems), and 50 ml
pre-washed protein G agarose for 4 hr with gentle rocking. The resin was
then washed repeatedly with lysis buffer and eluted by boiling in denaturing
sample buffer.
AXL was blotted using an antibody against the receptor (Cell Signaling
Technologies, #4566), and Gas6 was blotted using the ELISA detection anti-
body or another antibody against the ligand (Abcam, #ab136249).
AXL Mutant and siRNA Transfection
AXL mutants were blunt-end cloned into pIRESpuro2 (Clontech) from wild-
type human cDNA to create a kinase-dead (K567R) mutant. 500,000 cells
were seeded in 10-cm plates. The next day, cells were transfected with
10 mg DNA of each AXL mutant using 10 ml Lipofectamine in Opti-MEM (Life
Technologies) according to the manufacturer’s instructions. Four hours
post-transfection, growthmedia were added back to the cells. After 24 hr, cells
were starved 4 hr and then lysed.
For siRNA treatment, plates were transfected with 5 ml Dharmafect 4 and
125 fmol of pooled siRNA in Opti-MEM and then placed back in full serum
media 4 hr later. Two days after transfection, cells were starved for 4 hr and
then lysed. Oligonucleotides against human transcripts were (50–30): siControl
ON-TARGETplus Non-targeting Pool D-001810-10-05, siAXL (pooled four
siRNAs) ON-TARGETplus SMARTpool siRNA L-003104-00, siGas6 (pooled
four siRNAs) ON-TARGETplus SMARTpool siRNA L-009069-00.
Immunofluorescence
Coverslips were coated with 100 mg/ml collagen I in 20 mM acetic acid and
then seeded with cells in the presence or absence of warfarin. Cells were fixed
24 hr later with 4% paraformaldehyde (PFA) in PHEM buffer. Fixed cells were
permeabilized with 0.1% Triton X-100 and 1% BSA in PBS and then blocked
for 30 min using Odyssey blocking buffer (OBB; LI-COR Biosciences). The pri-
mary antibody (R&D Systems: AXL monoclonal antibody MAB154, 5 mg/ml)
was incubated for 1 hr at room temperature in OBB. After washing with 1%
BSA in PBS, cells were incubated with phalloidin and secondary antibodies
for 1 hr and finally washed with 1% BSA in PBS.
For bead-based stimulation, Gas6 was coupled to polystyrene beads
following identical methods to the capture antibodies. Coupled beads were
washed six times to remove uncoupled protein. Cells were starved for 4 hr,
and then beads were added and allowed to settle for the indicated amount
of time. 4% PFA in PHEM buffer with phosphatase inhibitor (Boston
Bioproducts) was used to fix the cells for 10 min. Immunofluorescence was
performed by standard methods, with 1 mg/ml phosphotyrosine antibody
(P-Tyr-100, Cell Signaling Technology).
Imaging was performed using a CARVII spinning disk confocal microscope
with a 403 objective. Stacks were imaged every 1 mm and then processed by
maximum projection.Cell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc. 33
Model Parameterization
AXL signaling kinetics was modeled using ordinary differential equations, and
the model layout was inferred from structural understanding of ligand binding
(Sasaki et al., 2006). A0, A1, A2, and A12 indicate AXL in an unbound state,
bound at the high-affinity site, bound at the low-affinity site, and bound at
both sites, respectively. D1 indicates the dimer species with one Gas6 mole-
cule bridging receptors. D2 indicates the full receptor-ligand complex with
two Gas6 molecules dimerizing two receptors. Phosphorylation was assumed
to occur fast, so that species abundance directly translated to phosphorylated
receptor abundance (Monast et al., 2012). Dimerization of receptors to form
the D2 species was modeled as a one-step reaction implicitly assuming the
second binding after dimerization through the first interface was fast. As the
local concentration of incompletely dimerized Gas6 would be in excess of
1 M in the intermediate state, we believe that this is a suitable assumption.
The forward rates of receptor dimerization were assumed to be equal. Ig1-
binding rates were set according to previous measurements (Kariolis et al.,
2014). The on rate of Ig2 binding, kfb2, was set to 10
7M1s1, as binding affinity
is rarely governed by distinct on rates. The reverse reaction rate for dimeriza-
tion reaction 1, kr1, was assumed to be equal to the reverse binding rate of Ig2,
krb2, as a single ligand is the sole bridge between receptors, and the off rate of
Ig2 is at least 100-fold higher than that of Ig1. Autocrine ligandwas assumed to
be present at a constant concentration, with stimulated ligand adding to that
concentration.
dA0
dt
= krb1A1 + krb2A2 + ðkr1 + kr2ÞD1 + kr3D2 + n ðkf1A1 + kf2A2 + kf3A12 + kfb1G
+ kfb2GÞA0:
dA1
dt
= kfb1GA0  krb1A1  kfb2GA1 + krb2A12  kf1A0A1 + kr1D1  2kf4A21 + 2kr4D2:
dA2
dt
= kfb2GA0 + krb1A12 + kr2D1 + 2kr5D2  ðkrb2 + kfb1G+ kf2A0 + 2kf5A2ÞA2:
dA12
dt
= ðkfb2A1 + kfb1A2ÞG ðkrb1 + krb2 + kf3A0ÞA12 + kr3D2:
dD1
dt
= kr6D2 + kf2A0A2 + kf1A0A1  ðkf6G+ kr2 + kr1ÞD1:
dD2
dt
= kf6D1G+ kf5A
2
2 + kf4A
2
1 + kf3A0A12  ðkr3 + kr6 + kr5 + kr4ÞD2:
A subset of parameters was constrained due to detailed balance, as indicated
in Figure 2A.
Trafficking was modeled and kinetically constrained based on understand-
ing from other RTKs (French and Lauffenburger, 1997; Monast et al., 2012). We
first assumed that endocytosis and endosomal sorting of each species
occurred according to phosphorylation state. A faster phosphorylation-
dependent rate ðkint;2Þ and a slower phosphorylation-independent rate ðkint;1Þ
were included, as observed with other RTK families (Monast et al., 2012).
Fluid-phase uptake of ligand was assumed to not occur, as its contribution
has only been observed at very high extracellular concentrations. Endosomal
maturation and degradation were modeled as done previously, with no sorting
of ligand. The ligand compartment was assumed to constitute 2% of the
cellular volume, or 10 fl per cell, and the endosomal surface area was assumed
to be half that of the plasmamembrane. Receptor and ligand interactions were
assumed to be identical within the endosomal compartment. Trafficking was
defined by:
dX
dt
=  Xðkint;1 +Sakint;2Þ+ krecð1 fÞgXi ; and
dXi
dt
=
X
g
ðkint;1 +Sakint;2Þ  krecð1 fÞXi  kdegfXi :
f is the sorting fraction for each species, which is the fractional propensity of a
species to be degraded instead of recycled. As such, f =1means that all of that
endocytosed species is degraded, and f = 0 means that all is recycled. f is felse
for non-phosphorylated species and 1 for phosphorylated ones.34 Cell Systems 1, 25–36, July 29, 2015 ª2015 Elsevier Inc.The model was implemented as an external library to MATLAB 2013b in
C++ using CVode, using the backward differentiation formula and Newton
iteration, with the dense Jacobian solver (Hindmarsh et al., 2005). Integration
was performed for 10,000 min in order to ensure that the model had arrived
at equilibrium in the presence of autocrine ligand before the addition of
exogenous stimulus at t = 0. c2 values were calculated from the SE of
each measurement, for the A549 cell line, using experimental replicates. At
least 1,000 independent times, global optimization was performed from
a random starting point using the direct search method patternsearch
within MATLAB. Multiple independent optimization trials were confirmed to
converge on the same optimal fit. All code used is available as a supplement
or online with further documentation for extended usage at (https://github.
com/thanatosmin/AXLdiffEQ).
For validation of model predictions in the U87 cell line, each parameter set
was adjusted by fitting only AXL expression and autocrine Gas6 abundance
to the U87 data and then plotted over the measured values.
Spatial Modeling
Spatial modeling was performed by finite differencing on a two-dimensional,
radially symmetric geometry of radius L, integrated using CVode (Hindmarsh
et al., 2005). Within the region of interest, diffusion was modeled using explicit
central difference approximation:
dcx;i
Dxdt
=
4cx;i + ð2 i1Þcx;i1 + ð2+ i1Þcx;i +1
2U
;
where Dx is the diffusion coefficient of species x, cx,i is the concentration of
species x at discrete position i, i is the index of each discretized point along
the radius of the region of interest, and U = L2 N2, where N is the number
of discretized points along the radius.
As diffusion is the only parameter that defines the length scale of the system,
other lengths are defined in terms of L. r = Lwas set as a closed boundary, and
at r = 0, the solution was assumed to be finite. As such, diffusion at the bound-
aries was calculated to be:
dcx;0
Dxdt
=
4
U
ðcx;1  cx;0Þ; and
dcx;L
Dxdt
=
4
U
ðcx;L  cx;L1Þ:
Diffusion was selected to occur for A0 and internal species, as Gas6 binding
was assumed to reduce mobility. Reactions occurred normally throughout
the region of interest unless noted otherwise. The extracellular Gas6 concen-
tration profile was fixed as:
½Gas6= 64 cos
pr
3L
s
;
where s is a ‘‘spatial inhomogeneity’’ parameter.
Simplified Model of Clustering Effect
Based on the assumption that local receptor density is limiting to activation, we
constructed a simplified two-compartment model in which receptor activity is
related proportionally and exclusively to local receptor density. Receptor was
assumed to partition between a PtdSer-interacting and PtdSer-absent
compartment with partition coefficient K, with a defined fractional surface
area x of the former compartment. The amount of phosphorylated receptor
(Y) is, therefore, defined as:
Y =b2x + c2ð1 xÞ;
where b and c represent the local receptor densities of each compartment.
After conservation of total receptor mass, the amount of phosphorylated re-
ceptor thus becomes:
Y =
K2x + 1 x
ðKx + 1 xÞ2:
We assumed K = 5 based on the intensities of spots observed in immuno-
fluorescence and experimentally determined the relationship between
fractional surface coverage and lipid concentration based on the response
observed.
Calculation of Binding Fractional Occupancy
The fractional binding of each ligand-receptor interaction surface was calcu-
lated according to equilibrium binding, ignoring the contributions of any traf-
ficking or dimerization processes. Thus, the fraction of receptor unbound is
defined as:
x =
KD
KD + L
;
where L is the ligand concentration, and KD is the ratio of the off-to-on rate of
receptor-ligand binding.
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